London · Delayed Price · Currency is GBP · Price in GBX ImmuPharma Statistics
Total Valuation
ImmuPharma has a market cap or net worth of GBP 58.32 million. The enterprise value is 57.92 million.
| Market Cap | 58.32M |
| Enterprise Value | 57.92M |
Important Dates
The next estimated earnings date is Monday, November 10, 2025.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuPharma has 502.72 million shares outstanding. The number of shares has increased by 11.06% in one year.
| Current Share Class | 502.72M |
| Shares Outstanding | 502.72M |
| Shares Change (YoY) | +11.06% |
| Shares Change (QoQ) | +15.22% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 82.27% |
| Float | 461.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 173.20 |
| P/TBV Ratio | 175.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.72 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.50 |
Financial Position
The company has a current ratio of 1.21
| Current Ratio | 1.21 |
| Quick Ratio | 0.73 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.55 |
Financial Efficiency
Return on equity (ROE) is -259.88% and return on invested capital (ROIC) is -129.66%.
| Return on Equity (ROE) | -259.88% |
| Return on Assets (ROA) | -69.57% |
| Return on Invested Capital (ROIC) | -129.66% |
| Return on Capital Employed (ROCE) | -932.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -655,754 |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -199,359 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +643.59% in the last 52 weeks. The beta is 2.79, so ImmuPharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.79 |
| 52-Week Price Change | +643.59% |
| 50-Day Moving Average | 9.91 |
| 200-Day Moving Average | 4.67 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 4,403,047 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.14M |
| Pretax Income | -4.13M |
| Net Income | -3.93M |
| EBITDA | -3.14M |
| EBIT | -3.14M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 396,648 in cash and n/a in debt, giving a net cash position of 396,648 or 0.00 per share.
| Cash & Cash Equivalents | 396,648 |
| Total Debt | n/a |
| Net Cash | 396,648 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 336,699 |
| Book Value Per Share | 0.00 |
| Working Capital | 257,412 |
Cash Flow
In the last 12 months, operating cash flow was -1.90 million and capital expenditures -1,652, giving a free cash flow of -1.90 million.
| Operating Cash Flow | -1.90M |
| Capital Expenditures | -1,652 |
| Free Cash Flow | -1.90M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ImmuPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.06% |
| Shareholder Yield | -11.06% |
| Earnings Yield | -6.75% |
| FCF Yield | -3.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |